[Home](/)/[Resources](/resources)/Class IIa / IIb Medical Devices UK

UKMedical Devices

# Class IIa and IIb Medical Devices: UK Clinical Data and Conformity Requirements

The path from device classification to UKCA marking for Class IIa and Class IIb medical devices under UK MDR 2002 is more demanding than it was under the old MDD transitional arrangements — and the clinical evidence requirements have teeth. This guide breaks down exactly what the MHRA and UK Approved Bodies expect: how to apply the classification rules, what goes into a defensible Clinical Evaluation Report, which conformity assessment route applies, and how the post-Brexit regulatory split between Great Britain and Northern Ireland affects your market access strategy.

Copy Link[Share on WhatsApp](https://wa.me/?text=https%3A%2F%2Fkrono-labs.com%2Fguides%2Fuk-medical-device-class-iia-iib)

At a glance

Classification body

MHRA (UK)

Key legislation

UK MDR 2002 (as amended)

UK Approved Body required

Yes — Class IIa and IIb

Registration

MHRA Device Registration before sale

## Key regulatory concepts for Class IIa and IIb devices in the UK

### Class IIa vs IIb — the classification decision

Rule 10 (software), Rule 11 (active therapeutic devices), and Rule 12 (active devices for diagnosis) are the primary classification rules for this segment. Class IIa covers devices whose principal intended action is achieved by physical means — diagnostic imaging equipment, non-active surgical instruments intended for short-term invasive use (≤30 days), corrective contact lenses, and digital stethoscopes fall here. Class IIb covers devices whose principal intended action is achieved by conversion of energy, or active therapeutic devices intended to administer or exchange energy with the patient in a potentially hazardous way. Key Class IIb examples include ventilators, infusion pumps, surgical lasers, and high-frequency electrosurgical units. Getting the classification right at the outset is critical — it determines which conformity assessment route, which UK Approved Body workload, and how deep the clinical evidence bar sits.

### UK MDR 2002 vs EU MDR 2017 — the post-Brexit split

Since 1 January 2021, Great Britain (England, Scotland, Wales) operates under UK MDR 2002 as amended by the Medical Devices (Amendment) (EU Exit) Regulations 2019. Northern Ireland continues to apply EU MDR 2017 under the Windsor Framework — it remains aligned with EU product law, not GB law. From 1 July 2025, new Class IIa and IIb devices for the GB market require UKCA marking via a UK Approved Body. CE-marked devices placed on the GB market under the transitional grace period before 30 June 2025 received temporary coverage; that window is now closed and UKCA is the primary route for new placements. A device holding both CE and UKCA marking can access both the EU/NI and GB markets, but each certificate is issued separately — an EU Notified Body issues the CE certificate, a UK Approved Body issues the UKCA certificate.

### Clinical evaluation — Article 61 EU MDR equivalent in UK law

UK MDR 2002 Schedule 5 Part III and the MHRA's clinical evaluation guidance require a Clinical Evaluation Report (CER) for all Class IIa and IIb devices. The CER must systematically identify and appraise all clinical data for the device and equivalent devices; demonstrate conformity with the general safety and performance requirements; set out the clinical benefit-risk conclusion; and reference post-market clinical follow-up (PMCF) activities. For Class IIb devices, the evidence bar is materially higher — systematic literature reviews alone are typically insufficient without clinical investigation data or rigorously documented equivalence data. The MHRA's guidance on clinical evaluation closely mirrors MDCG 2020-5 from the EU, making the two frameworks practically comparable in their CER demands.

### UK Approved Bodies — what they replaced and who they are

UK Approved Bodies are UK-designated conformity assessment organisations that replaced EU Notified Bodies for UKCA marking purposes. They are designated by MHRA and listed on the MHRA website. Key UK Approved Bodies for medical devices include BSI (Kitemark Court), SGS UK, Intertek, and TÜV SÜD UK. A UK Approved Body cannot issue a CE certificate — that requires an EU Notified Body — and an EU Notified Body cannot issue a UKCA certificate. For Class IIa devices, the UK Approved Body must review the technical documentation and quality management system under Annex II (full quality assurance) or Annex VII (production quality assurance). For Class IIb devices, the required routes are Annex II or Annex III (type examination) combined with Annex IV, V, or VI. Pre-submission dialogue is available with most UK Approved Bodies and is strongly recommended before a formal application.

### Technical documentation — the UK MDR Schedule 3 requirements

The technical file for a Class IIa or IIb device under UK MDR 2002 must include: device description and specification (covering all variants and accessories); reference to previous generations and similar devices; design and manufacturing information; a general safety and performance requirements (GSPR) checklist with cross-referenced supporting evidence; benefit-risk analysis; and complete product verification and validation data. Pre-clinical data requirements include biocompatibility per BS EN ISO 10993-1 (risk-based biological evaluation), electrical safety per BS EN 60601-1 (third edition), EMC per BS EN 60601-1-2 (fourth edition for electrically powered devices), software lifecycle documentation per BS EN 62304 for software-containing devices, and sterility validation per BS EN ISO 11135 or 11137 where applicable. The clinical evaluation report, post-market surveillance plan, compliant labelling, and instructions for use in English for the GB market round out the file.

### IVD vs general medical device classification — common misclassification

In vitro diagnostic devices are classified separately under the UK IVDR — a parallel regulatory framework with its own conformity assessment routes and UK Approved Body requirements. Devices that analyse blood, urine, or other body fluids are IVDs, not MDR devices, even when they have a substantial physical component. A point-of-care blood glucose monitor is an IVD; a blood pressure cuff is a Class IIa medical device under UK MDR. The most frequent misclassifications encountered in practice: companion diagnostics incorrectly routed through the MDR stream (they should be classified as IVDs), and digital health apps providing individual diagnosis placed as general consumer software when they may qualify as Class IIa medical devices under the software classification rules if they are intended to make individual diagnostic decisions that could affect patient management.

## Step-by-step UKCA conformity assessment process for Class IIa and IIb

01

Apply the UK MDR 2002 classification rules (Annex IX / Schedule 7 equivalent) to determine whether the device is Class IIa or Class IIb. Document the classification rationale, the specific rule applied (Rule 10, 11, or 12 for most active devices), and any boundary cases considered. The MHRA's classification guidance document is the primary reference for disputed classifications, and the MHRA Borderline and Classification Unit can be consulted for formal opinions.

02

Select the conformity assessment procedure based on the class determination. For Class IIa: Annex II (full quality assurance) or Annex VII (production quality assurance) combined with a clinical evaluation under Annex X. For Class IIb: Annex II (full QA system covering design dossier review) or Annex III (EC type examination) combined with Annex IV, V, or VI for ongoing production oversight.

03

Select a UK Approved Body from the MHRA's approved body register. Confirm the body holds designation for the device code corresponding to your specific device type — not all UK Approved Bodies hold designation across all device categories. Initiate pre-submission dialogue early in the process; UK Approved Bodies offer pre-submission meetings to identify documentation gaps before a formal application is logged, and this significantly reduces the risk of major deficiency notices mid-review.

04

Establish or certify your ISO 13485:2016 Quality Management System. ISO 13485 certification from a UKAS-accredited certification body is the standard evidence of a compliant QMS for UK MDR purposes. The QMS scope must cover design and development, production controls, complaint handling, and post-market surveillance. Some manufacturers already hold ISO 13485 certification for their EU MDR QMS — verify that the scope covers all device types and that the certificate is from a body accredited by UKAS or an equivalent ILAC MRA signatory.

05

Commission the pre-clinical test programme tailored to the device's risk profile. For Class IIa and IIb devices the standard battery includes: biocompatibility testing per BS EN ISO 10993-1 using a risk-based approach to biological evaluation endpoints; electrical safety per BS EN 60601-1 third edition including any applicable collateral and particular standards; EMC per BS EN 60601-1-2 fourth edition for electrically powered devices; software lifecycle documentation per BS EN 62304 if the device contains software (including cybersecurity risk management per IEC 81001-5-1 where applicable); and sterility validation per BS EN ISO 11135 (EO sterilisation) or 11137 (radiation sterilisation) if supplied sterile.

06

Prepare the Clinical Evaluation Report following the MHRA's clinical evaluation guidance. Identify the clinical data using a systematic literature search methodology — PICO framework (Population, Intervention, Comparison, Outcome) — covering device-specific clinical data and data from equivalent devices. Appraise the retrieved data for quality and relevance using recognised appraisal tools (AGREE II for guidelines, QUADAS-2 for diagnostic studies, Cochrane RoB for RCTs). Demonstrate conformity with the clinical performance and safety GSPR. For Class IIb devices, ensure clinical investigation data is available or that equivalence to an established device is rigorously demonstrated per the MHRA equivalence criteria — which require documented access to the equivalent device's technical documentation.

07

Compile the complete technical documentation per UK MDR 2002 Schedule 3 structure. The documentation must be organised to allow the UK Approved Body reviewer to efficiently navigate from GSPR to supporting evidence. Include all pre-clinical test reports (with test standards and pass/fail conclusions), the CER with appended literature search protocol and results, compliant labelling bearing the UKCA mark, UK Responsible Person details, reference number, and instructions for use in English for the GB market.

08

Submit to the UK Approved Body for technical documentation review and QMS audit. Realistic timelines: 3–6 months for a Class IIa device with complete documentation; 6–12 months for a Class IIb device. The UK Approved Body will issue deficiency notices during review — maintain a live deficiency tracker and assign resolution ownership internally. Upon satisfactory review and QMS audit, the UK Approved Body issues a UK Conformity Assessment certificate specifying the device, the conformity assessment route, and the certificate validity period.

09

Register the device on the MHRA Device Registration system before placing on the GB market. Class IIa and IIb devices must be registered — registration is distinct from conformity assessment and must be completed before first placement. Affix the UKCA mark (for GB) or retain CE mark (for NI/EU). Issue the UK Declaration of Conformity referencing the applicable UK legislation and the UK Approved Body certificate number. Establish and activate the post-market surveillance system and PMCF plan per UK MDR Schedule 3 Part B requirements, with the first PMCF evaluation report timeline documented.

## Frequently asked questions

### What clinical data is required for a Class IIa medical device in the UK?

UK MDR 2002 requires a Clinical Evaluation Report for all Class IIa devices. The CER must be based on a systematic appraisal of all available clinical data — published literature on the device and equivalent devices, clinical investigation data if available, and post-market surveillance data. For Class IIa devices where equivalence to an existing well-characterised device can be demonstrated, a literature-based CER may be sufficient, provided the equivalence is established on technical, biological, and clinical grounds. The MHRA's clinical evaluation guidance — which closely mirrors MDCG 2020-5 — requires the equivalence claim to be substantiated with documented access to the equivalent device's technical documentation, meaning a mere assertion of equivalence without data access is insufficient.

### Do Class IIa devices in the UK need a UK Approved Body?

Yes. Since 1 July 2025, Class IIa and Class IIb devices placed on the Great Britain market require UKCA marking via a UK Approved Body designated by MHRA. The UK Approved Body reviews the manufacturer's technical documentation and quality management system, and issues a UK Conformity Assessment certificate. Class IIa devices use Annex II (full quality assurance) or Annex VII (production quality assurance) conformity assessment routes. Class I non-sterile, non-measuring devices self-declare without involving a UK Approved Body. Class IIb requires Annex II or Annex III type examination — the latter involves the UK Approved Body examining a device specimen alongside the full technical documentation and issuing a type examination certificate before production can proceed.

### Can a CE-marked medical device still be sold in Great Britain?

Since the end of the transitional period on 30 June 2025, new devices for the Great Britain market require UKCA marking. Devices that were CE-marked and placed on the GB market or registered before the transitional deadline may continue to be sold through existing distributor stock. Northern Ireland continues to accept CE-marked devices under EU MDR 2017 by virtue of the Windsor Framework — a product with a valid CE certificate from an EU Notified Body can be placed on the NI market without UKCA. Manufacturers targeting both GB and NI or EU markets typically pursue dual marking: UKCA via a UK Approved Body and CE via an EU Notified Body. These are two entirely separate conformity assessment processes resulting in two separate certificates, even if the underlying technical documentation is largely shared.

### What is the difference between Class IIa and Class IIb in practical terms for conformity assessment?

The fundamental regulatory difference lies in the required conformity assessment route and the depth of UK Approved Body scrutiny. For Class IIa, the UK Approved Body reviews the QMS and a representative sample of technical documentation — they do not examine the complete technical file for every device variant. For Class IIb, the UK Approved Body must review the complete technical documentation for each device under Annex III type examination, or implement the full Annex II QA system covering a design dossier review. This means Class IIb involves substantially more time and cost — typically 6–12 months versus 3–6 months for Class IIa — and a materially more demanding clinical evidence standard that rarely accommodates literature-only CERs.

**Disclaimer:** Educational resource only. Regulatory requirements change — in particular, UK MDR 2002 continues to be amended post-Brexit and MHRA guidance is updated regularly. Consult a qualified regulatory affairs specialist and, where appropriate, your UK Approved Body before making compliance decisions.

🇬🇧 UK roadmap for your product

Every standard, document, and test that applies — free, no account required.

See your free roadmap

Learn this properly

In-depth course that teaches the full process, not just this one answer.

[Start the course — $149](/courses/09-ukca-marking-for-electronics-products)[Prefer to read? Get the book — $24.99](/books/09-ukca-marking-for-electronics-products)

Related guides

*   [UK Medical Devices MHRAComplete guide to UK medical device regulations: MHRA registration, UKCA marking, classification, conformity assessment, and po…](/guides/uk-medical-devices-mhra)
*   [UK Medical Device Clinical EvaluationComplete guide to UK medical device clinical evaluation requirements under MHRA regulations: what clinical evaluation must demo…](/guides/uk-medical-device-clinical-evaluation)
*   [UK Approved Body vs EU Notified BodyComplete guide to UK Approved Bodies vs EU Notified Bodies: what changed after Brexit, which products require third-party asses…](/guides/uk-approved-body-vs-notified-body)
*   [UK In-Vitro Diagnostic DevicesComplete guide to UK In-Vitro Diagnostic Medical Device Regulations 2022 for Great Britain: IVDR classification (A, B, C, D), M…](/guides/uk-medical-devices-ivd)
*   [CE marking for medical devices: MDR vs general CEUnderstand the difference between CE marking under the Medical Device Regulation (MDR) and general CE marking directives.](/guides/ce-marking-for-medical-devices-mdr)